Key result
Implantation of a bioprosthetic aortic valve treated with a novel anti-calcification technology resulted in 0% valve-related mortality, structural valve deterioration, or major paravalvular leak at one year.
Why the study?
Does a bioprosthetic aortic valve treated with a novel anti-calcification technology demonstrate safety and improved haemodynamic performance in patients with severe aortic stenosis?
Observational (n=20)
No
Does a bioprosthetic aortic valve treated with a novel anti-calcification technology demonstrate safety and improved haemodynamic performance in patients with severe aortic stenosis?
Early clinical experience with a novel anti-calcification bioprosthetic aortic valve demonstrated excellent safety, durability, and haemodynamic performance at one year.
No takes yet. Share an insight, caveat, or question.
Promising one-year safety data should not yet change valve selection; leaves open durability and comparative efficacy versus standard bioprostheses.
Sadowski et al. (2015) conducted an observational in Severe aortic stenosis (n=20). Bioprosthetic aortic valve treated with novel anti-calcification technology (GLX) was evaluated on Primary safety endpoints (valve-related mortality, thromboembolic events, valve thrombosis, major bleeding, major paravalvular leak, endocarditis, structural valve deterioration, haemolysis, and valve-related reoperation). Implantation of a bioprosthetic aortic valve treated with a novel anti-calcification technology resulted in 0% valve-related mortality, structural valve deterioration, or major paravalvular leak at one year.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: